Summary
Soft Tissue Sarcoma Market Research Report Information By Diagnosis (Biopsy, Ultrasound Scan, Magnetic Resonance Imaging (MRI), and others), By Treatment (Targeted Therapy, Chemotherapy, Anti-Angiogenesis Drugs, Radiation Therapy, and Surgery) By End Use (Hospitals and Clinics, Cancer Research Centers, and Others), And By Region (North America, Europe, Asia-Pacific, And Rest of the World) Industry Forecast Till 2032
Market Overview
The Soft Tissue Sarcoma Market Size was estimated to be USD 3,248.52 Million in 2023 and is expected to increase to USD 6,204.02 Million by 2032, with a compound annual growth rate (CAGR) of 7.67% during the forecast period (2024-2032). The primary market drivers that contribute to market growth include the introduction of new products, the increased utilization of innovative therapies, and a broader target population.
The introduction of new products, the prevalent use of innovative medicines, and an expansion of the target audience are among the key market drivers that are driving market growth. The discovery and development of novel therapeutics are significant factors that are driving the soft tissue sarcoma market. The availability of innovative medications and therapies for the treatment of soft tissue sarcoma has exploded in the past decade. The expanded treatment options and enhanced effectiveness that these groundbreaking pharmaceuticals enable are advantageous to both patients and physicians.
Market segment insights
Angiosarcoma, Epithelioid Sarcoma, Gastrointestinal Stromal Tumor (GIST), and Others comprise the global soft tissue sarcoma market, which is segmented according to its type. The Gastrointestinal Stromal Tumor (GIST) segment is the fastest growing segment during the forecast period, while the Angiosarcoma segment held the largest market in 2023.
The Global Soft Tissue Sarcoma Market has been segmented into Diagnosis and Treatment. The Diagnostic segment was the largest market in 2023, and the Treatment segment is the fastest-growing segment during the forecast period. The diagnosis is further divided into the following categories: Ultrasound Scan, Magnetic Resonance Imaging (MRI), Biopsy, and others, such as PET scan and X-ray. Targeted therapy, chemotherapy, radiation therapy, antiangiogenic drugs, and surgery comprise the treatment regimen.
The Global Soft Tissue Sarcoma Market has been segmented into Hospitals and Clinics, Cancer Research Centers, and others based on End User. The Hospitals and Clinics segment is the fastest-growing segment during the forecast period and held the largest market in 2023.
Regional Perspectives
The study offers market insights into North America, Europe, Asia-Pacific, and the Rest of the World by region. In 2022, the soft tissue sarcoma market was primarily dominated by North America, with Europe and the Asia-Pacific region following in that order. This is due to the high prevalence of soft tissue sarcoma in North America and Europe, as well as the presence of modern healthcare infrastructure and R&D activity in these regions.
The European Soft Tissue Sarcoma market is the second greatest shareholder in the global market. In December 2021, the European Medicines Agency (EMA) granted conditional marketing authorization for Tazverik (tazemetostat) for the treatment of epithelioid sarcoma in adults.
Additionally, the Asia Pacific Soft Tissue Sarcoma market is anticipated to experience the most rapid compound annual growth rate (CAGR) during the forecast period. In September 2021, the China National Medical Products Administration (NMPA) approved Ayvakit (avapritinib) for the treatment of unresectable or metastatic gastrointestinal stromal tumors (GIST), a type of soft tissue sarcoma.
Major Players
GlaxoSmithKline plc (U.K.), Eli Lilly and Company (U.S.), Pfizer Inc. (U.S.), Bristol-Myers Squibb (U.S.), F. Hoffmann-La Roche AG (Genentech) (Switzerland), Johnson & Johnson Services Inc. (U.S.), and others are among the major players in the Soft Tissue Sarcoma market.
ページTOPに戻る
Table of Contents
TABLE OF CONTENTS
1 EXECUTIVE SUMMARY .............................................................................................................. 20
2 MARKET INTRODUCTION ............................................................................................................ 22
2.1 DEFINITION .................................................................................................................................................................. 22
2.2 SCOPE OF THE STUDY .............................................................................................................................................. 22
2.3 RESEARCH OBJECTIVE ............................................................................................................................................ 22
2.4 MARKET STRUCTURE .............................................................................................................................................. 22
3 RESEARCH METHODOLOGY ...................................................................................................... 23
3.1 OVERVIEW .................................................................................................................................................................... 23
3.2 DATA FLOW .................................................................................................................................................................. 25
3.2.1 DATA MINING PROCESS ................................................................................................................................. 25
3.3 PURCHASED DATABASE: ......................................................................................................................................... 26
3.4 SECONDARY SOURCES: ............................................................................................................................................ 27
3.4.1 SECONDARY RESEARCH DATA FLOW: ............................................................................................................. 28
3.5 PRIMARY RESEARCH: ............................................................................................................................................... 29
3.5.1 PRIMARY RESEARCH DATA FLOW: ................................................................................................................. 30
3.6 APPROACHES FOR MARKET SIZE ESTIMATION: ........................................................................................... 31
3.6.1 REVENUE ANALYSIS APPROACH ..................................................................................................................... 31
3.7 DATA FORECASTING................................................................................................................................................. 32
3.7.1 DATA FORECASTING TYPE .............................................................................................................................. 32
3.8 DATA MODELING ........................................................................................................................................................ 33
3.8.1 MICROECONOMIC FACTOR ANALYSIS: ............................................................................................................ 33
3.8.2 DATA MODELING: ........................................................................................................................................... 34
3.9 TEAMS AND ANALYST CONTRIBUTION ........................................................................................................... 36
4 MARKET DYNAMICS .................................................................................................................... 38
4.1 INTRODUCTION ........................................................................................................................................................... 38
4.2 DRIVERS ......................................................................................................................................................................... 39
4.2.1 INCREASING INCIDENCE OF SOFT TISSUE SARCOMAS ..................................................................................... 39
4.2.2 RISING AWARENESS ASSOCIATED WITH SOFT TISSUE SARCOMA .................................................................... 39
4.2.3 GROWING APPROVAL OF INNOVATIVE TREATMENT FOR SOFT TISSUE SARCOMA ............................................ 40
4.3 RESTRAINTS ................................................................................................................................................................ 42
4.3.1 SIDE-EFFECTS OF SOFT TISSUE SARCOMA DRUGS ........................................................................................... 42
4.3.2 VOLUNTARY PRODUCT RECALLS BY MARKET PLAYERS ................................................................................... 42
4.4 OPPORTUNITY ............................................................................................................................................................. 44
4.4.1 GROWING GERIATRIC POPULATION ................................................................................................................ 44
4.4.2 INVESTMENTS IN RESEARCH AND DEVELOPMENT .......................................................................................... 44
4.4.3 ONGOING CLINICAL TRIALS FOR SOFT TISSUE SARCOMA ................................................................................ 45
5 MARKET FACTOR ANALYSIS ...................................................................................................... 46
5.1 PORTER'S FIVE FORCES MODEL ........................................................................................................................... 46
5.1.1 THREAT OF NEW ENTRANTS ........................................................................................................................... 46
5.1.2 BARGAINING POWER OF SUPPLIERS ............................................................................................................... 47
5.1.3 THREAT OF SUBSTITUTES .............................................................................................................................. 47
5.1.4 BARGAINING POWER OF BUYERS .................................................................................................................... 47
5.1.5 INTENSITY OF RIVALRY .................................................................................................................................. 47
5.2 IMPACT OF COVID-19 ON GLOBAL SOFT TISSUE SARCOMA MARKET ................................................... 48
5.3 KEY MARKET TRENDS IN THE CHINA SOFT TISSUE SARCOMA MARKET ......................................... 49
5.4 TECHNOLOGICAL ADVANCEMENTS IN CHINA ............................................................................................... 50
5.5 REGULATORY FRAMEWORK IN CHINA ............................................................................................................. 52
5.6 PIPELINE ANALYSIS IN CHINA ............................................................................................................................. 53
5.7 AVERAGE PRICING OF PRODUCTS IN CHINA, 2023 ........................................................................................ 56
6 GLOBAL SOFT TISSUE SARCOMA MARKET, BY TYPE ............................................................. 58
6.1 OVERVIEW .................................................................................................................................................................... 58
6.2 ANGIOSARCOMA ........................................................................................................................................................ 60
6.3 EPITHELIOID SARCOMA .......................................................................................................................................... 61
6.4 GASTROINTESTINAL STROMAL TUMOR (GIST) ............................................................................................. 61
6.5 OTHERS .......................................................................................................................................................................... 62
7 GLOBAL SOFT TISSUE SARCOMA MARKET, BY DIAGNOSIS AND TREATMENT ................... 63
7.1 OVERVIEW .................................................................................................................................................................... 63
7.2 DIAGNOSIS .................................................................................................................................................................... 65
7.2.1 BIOPSY .......................................................................................................................................................... 66
7.2.2 ULTRASOUND SCAN ....................................................................................................................................... 66
7.2.3 MAGNETIC RESONANCE IMAGING (MRI) ......................................................................................................... 67
7.2.4 OTHERS ......................................................................................................................................................... 67
7.3 TREATMENT................................................................................................................................................................ 68
7.3.1 TARGETED THERAPY ...................................................................................................................................... 69
7.3.2 CHEMOTHERAPY ............................................................................................................................................ 69
7.3.3 ANTI-ANGIOGENESIS DRUGS ..................................................................................................................... 70
7.3.4 RADIATION THERAPY ..................................................................................................................................... 70
7.3.5 SURGERY ....................................................................................................................................................... 71
8 GLOBAL SOFT TISSUE SARCOMA MARKET, BY END USER .................................................... 72
8.1 OVERVIEW .................................................................................................................................................................... 72
8.2 HOSPITALS AND CLINICS ........................................................................................................................................ 74
8.3 CANCER RESEARCH CENTERS .............................................................................................................................. 75
8.4 OTHERS .......................................................................................................................................................................... 75
9 GLOBAL SOFT TISSUE SARCOMA MARKET, BY REGION ........................................................ 76
9.1 OVERVIEW .................................................................................................................................................................... 76
9.2 NORTH AMERICA ....................................................................................................................................................... 77
9.2.1 US.................................................................................................................................................................. 81
9.2.2 CANADA ........................................................................................................................................................ 83
9.3 EUROPE .......................................................................................................................................................................... 85
9.3.1 GERMANY ...................................................................................................................................................... 89
9.3.2 FRANCE ......................................................................................................................................................... 91
9.3.3 UK ................................................................................................................................................................. 93
9.3.4 ITALY ............................................................................................................................................................. 95
9.3.5 SPAIN ............................................................................................................................................................ 97
9.3.6 RUSSIA .......................................................................................................................................................... 99
9.3.7 REST OF EUROPE ............................................................................................................................................ 101
9.4 ASIA-PACIFIC ............................................................................................................................................................... 103
9.4.1 CHINA ............................................................................................................................................................ 107
9.4.2 INDIA ............................................................................................................................................................. 109
9.4.3 JAPAN ........................................................................................................................................................... 111
9.4.4 SOUTH KOREA ................................................................................................................................................ 113
9.4.5 MALAYSIA ..................................................................................................................................................... 115
9.4.6 THAILAND ...................................................................................................................................................... 117
9.4.7 INDONESIA ..................................................................................................................................................... 119
9.4.8 REST OF ASIA-PACIFIC ................................................................................................................................... 121
9.5 SOUTH AMERICA ....................................................................................................................................................... 123
9.5.1 BRAZIL ........................................................................................................................................................... 127
9.5.2 MEXICO ......................................................................................................................................................... 129
9.5.3 ARGENTINA ................................................................................................................................................... 131
9.5.4 REST OF SOUTH AMERICA .............................................................................................................................. 133
9.6 MIDDLE EAST AND AFRICA .................................................................................................................................... 135
9.6.1 GCC COUNTRIES............................................................................................................................................. 139
9.6.2 SOUTH AFRICA ............................................................................................................................................... 142
9.6.3 REST OF MIDDLE EAST AND AFRICA ................................................................................................................ 144
10 COMPETITIVE LANDSCAPE ........................................................................................................ 148
10.1 INTRODUCTION ........................................................................................................................................................... 148
10.2 MARKET SHARE ANALYSIS, 2023 ....................................................................................................................... 148
10.3 COMPETITOR DASHBOARD..................................................................................................................................... 149
10.4 PUBLIC PLAYERS STOCK SUMMARY ................................................................................................................. 150
10.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL .............................................................................. 150
10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES ............................................................................................ 151
10.6.1 PRODUCT APPROVAL ..................................................................................................................................... 151
10.6.2 COLLABORATION ........................................................................................................................................... 151
10.6.3 PRODUCT LAUNCH ......................................................................................................................................... 151
11 COMPANY PROFILES .................................................................................................................. 152
11.1 GE HEALTHCARE ....................................................................................................................................................... 152
11.1.1 COMPANY OVERVIEW ..................................................................................................................................... 152
11.1.2 FINANCIAL OVERVIEW .................................................................................................................................... 153
11.1.3 PRODUCTS/SERVICES OFFERED ...................................................................................................................... 154
11.1.4 KEY DEVELOPMENTS ...................................................................................................................................... 154
11.1.5 SWOT ANALYSIS ............................................................................................................................................ 155
11.1.6 KEY STRATEGIES ............................................................................................................................................ 155
11.2 CANON MEDICAL SYSTEMS CORPORATION .................................................................................................... 156
11.2.1 COMPANY OVERVIEW ..................................................................................................................................... 156
11.2.2 FINANCIAL OVERVIEW .................................................................................................................................... 157
11.2.3 PRODUCT OFFERED ........................................................................................................................................ 157
11.2.4 KEY DEVELOPMENTS ...................................................................................................................................... 158
11.2.5 KEY STRATEGIES ............................................................................................................................................ 158
11.3 NOVARTIS AG .............................................................................................................................................................. 159
11.3.1 COMPANY OVERVIEW ..................................................................................................................................... 159
11.3.2 FINANCIAL OVERVIEW .................................................................................................................................... 160
11.3.3 PRODUCTS OFFERED ...................................................................................................................................... 160
11.3.4 KEY DEVELOPMENTS ...................................................................................................................................... 161
11.3.5 SWOT ANALYSIS ............................................................................................................................................ 161
11.3.6 KEY STRATEGIES ............................................................................................................................................ 161
11.4 F. HOFFMANN-LA ROCHE LTD. ............................................................................................................................. 163
11.4.1 COMPANY OVERVIEW ..................................................................................................................................... 163
11.4.2 FINANCIAL OVERVIEW .................................................................................................................................... 164
11.4.3 PRODUCTS OFFERED ...................................................................................................................................... 164
11.4.4 KEY DEVELOPMENTS ...................................................................................................................................... 164
11.4.5 SWOT ANALYSIS ............................................................................................................................................ 165
11.4.6 KEY STRATEGIES ............................................................................................................................................ 166
11.5 BLUEPRINT MEDICINES CORPORATION ............................................................................................................ 167
11.5.1 COMPANY OVERVIEW ..................................................................................................................................... 167
11.5.2 FINANCIAL OVERVIEW .................................................................................................................................... 168
11.5.3 PRODUCTS OFFERED ...................................................................................................................................... 168
11.5.4 KEY DEVELOPMENTS ...................................................................................................................................... 169
11.5.5 KEY STRATEGIES ............................................................................................................................................ 169
11.6 JOHNSON & JOHNSON INC. ..................................................................................................................................... 170
11.6.1 COMPANY OVERVIEW ..................................................................................................................................... 170
11.6.2 FINANCIAL OVERVIEW .................................................................................................................................... 171
11.6.3 PRODUCTS OFFERED ...................................................................................................................................... 171
11.6.4 KEY DEVELOPMENTS ...................................................................................................................................... 172
11.6.5 SWOT ANALYSIS ............................................................................................................................................ 172
11.6.6 KEY STRATEGIES ............................................................................................................................................ 172
11.7 BRISTOL-MYERS SQUIBB COMPANY .................................................................................................................. 173
11.7.1 COMPANY OVERVIEW .................................................................................................................................... 173
11.7.2 FINANCIAL OVERVIEW .................................................................................................................................... 174
11.7.3 PRODUCTS OFFERED ...................................................................................................................................... 174
11.7.4 KEY DEVELOPMENTS ...................................................................................................................................... 175
11.7.5 KEY STRATEGIES ............................................................................................................................................ 175
11.8 EISAI CO., LTD .............................................................................................................................................................. 176
11.8.1 COMPANY OVERVIEW ..................................................................................................................................... 176
11.8.2 FINANCIAL OVERVIEW .................................................................................................................................... 177
11.8.3 PRODUCTS OFFERED ...................................................................................................................................... 177
11.8.4 KEY DEVELOPMENTS ...................................................................................................................................... 177
11.8.5 SWOT ANALYSIS ............................................................................................................................................ 178
11.8.6 KEY STRATEGIES ............................................................................................................................................ 178
11.9 SIEMENS HEALTHINEERS ...................................................................................................................................... 179
11.9.1 COMPANY OVERVIEW ..................................................................................................................................... 179
11.9.2 FINANCIAL OVERVIEW .................................................................................................................................... 180
11.9.3 PRODUCTS OFFERED ...................................................................................................................................... 180
11.9.4 KEY DEVELOPMENTS ...................................................................................................................................... 181
11.9.5 SWOT ANALYSIS ............................................................................................................................................ 181
11.9.6 KEY STRATEGIES ............................................................................................................................................ 182
11.10 ELI LILLY AND COMPANY ....................................................................................................................................... 183
11.10.1 COMPANY OVERVIEW ..................................................................................................................................... 183
11.10.2 FINANCIAL OVERVIEW .................................................................................................................................... 184
11.10.3 PRODUCTS OFFERED ...................................................................................................................................... 184
11.10.4 KEY DEVELOPMENTS ...................................................................................................................................... 185
11.10.5 KEY STRATEGIES ............................................................................................................................................ 185
12 DATA CITATIONS ......................................................................................................................... 186